RhumbLine Advisers’s AbCellera Biologics ABCL Stock Holding History

RhumbLine Advisers’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-135	Closed	-$301	–	4138
2025 Q1	$301	Hold	135	–	–	﹤0.01%	4074
2024 Q4	$395	Hold	135	–	–	﹤0.01%	4108
2024 Q3	$351	Hold	135	–	–	﹤0.01%	4133
2024 Q2	$399	Hold	135	–	–	﹤0.01%	4296
2024 Q1	$611	Buy	+135	New	+$689	﹤0.01%	4179
2023 Q3	–	Sell	-9,393	Closed	-$60.7K	–	4309
2023 Q2	$60.7K	Sell	9,393 -291,062	-97%	-$1.99M	﹤0.01%	3641
2023 Q1	$2.27M	Buy	300,455 +6,398	+2%	+$58.1K	﹤0.01%	1736
2022 Q4	$2.98M	Buy	294,057 +6,545	+2%	+$75.6K	﹤0.01%	1578
2022 Q3	$2.84M	Buy	287,512 +21,959	+8%	+$241K	﹤0.01%	1573
2022 Q2	$2.83M	Buy	+265,553	New	+$2.25M	﹤0.01%	1568

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

RhumbLine Advisers's ABCL Position: Q2 2025 in Review

RhumbLine Advisers sold out of AbCellera Biologics (ABCL) in Q2 2025, closing a stake of 135 shares — an estimated $301 sold.

RhumbLine Advisers first reported a position in ABCL in Q2 2022 and held it in 10 quarters. The position peaked at $2.98M in Q4 2022. 128 funds tracked by Wall St. Rank hold ABCL as of Q2 2025.

RhumbLine Advisers reported no remaining AbCellera Biologics position as of Q2 2025 after selling out during the quarter.
RhumbLine Advisers sold 135 AbCellera Biologics shares in Q2 2025, an estimated $301.
RhumbLine Advisers first reported a position in AbCellera Biologics in Q2 2022 and held it in 10 quarters.
RhumbLine Advisers's AbCellera Biologics position peaked at $2.98M in Q4 2022.
128 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.